Autologous cell therapy market seen reaching $22.6 billion by 2030

By AI, Created 11:20 AM UTC, May 20, 2026, /AGP/ – The Business Research Company says the market for autologous stem cell and non-stem cell therapies is projected to rise from $11.49 billion in 2025 to $22.59 billion by 2030. The report points to personalized medicine, manufacturing buildout and Asia-Pacific growth as key drivers.

Why it matters: - Autologous therapies use a patient’s own cells, which can lower immune rejection risk and support more personalized treatment. - The category is expanding alongside regenerative medicine, which has implications for cancer, autoimmune disease and degenerative disorder care. - The market’s projected rise signals more investment in cell therapy development, manufacturing capacity and clinical adoption.

What happened: - The Business Research Company released a 2026 market report on autologous stem cell and non-stem cell based therapies. - The market is projected to grow from $11.49 billion in 2025 to $13.31 billion in 2026, a 15.8% CAGR. - The market is expected to reach $22.59 billion by 2030, at a 14.1% CAGR. - The report is available as a free sample. - The full market report is available here.

The details: - Autologous stem cell therapies collect stem cells from the patient, expand or modify them in a lab, and reinfuse them to stimulate healing. - Non-stem cell therapies use other cell types, including immune cells or tissue-specific cells, to pursue similar therapeutic effects. - The report says growth in 2025 and 2026 is tied to degenerative disease prevalence, stem cell isolation advances, awareness of regenerative medicine, early adoption in developed markets and supportive government policy. - For the 2026-2030 period, the report points to rising investment in personalized medicine, manufacturing infrastructure for cell therapies, AI in therapy design, demand from emerging markets and combination cell-based treatments. - Key trends listed in the report include personalized regenerative therapies, immunomodulatory cell therapies, minimally invasive autologous procedures, cell expansion and manufacturing advances, and tissue engineering technologies. - The report says personalized medicine tailors treatment to a person’s genetic makeup, lifestyle and clinical profile. - The Personalized Medicine Coalition reported in February 2024 that about 38% of the 53 new therapeutic molecular entities approved by the U.S. FDA in 2023 were classified as personalized medicines. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast suggests autologous therapies are moving from niche use toward broader commercial and clinical relevance. - The regional split points to a mature market in North America and faster capacity building in Asia-Pacific. - The strong personalized medicine backdrop helps explain why cell-based treatments are attracting more attention from developers and investors.

What’s next: - The market’s next growth phase will likely depend on whether manufacturers can scale production and lower therapy complexity. - Adoption could accelerate if AI-assisted design and combination cell therapies deliver stronger clinical results. - More expansion in emerging markets could widen demand beyond current early adopters.

The bottom line: - Autologous stem cell and non-stem cell therapies are projected to more than double by 2030, with personalized medicine and manufacturing scale-up doing much of the work.